CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 200 enrolled
Drug / intervention
anti-SARS-CoV-2 convalescent plasmabiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04397523
NCT04397523N/ACompleted
CompareCT.gov

Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety

Institute for Transfusion Medicine of RNM·interventional·Posted May 21, 2020·Updated May 28, 2024

In Brief

A clinical study evaluating anti-SARS-CoV-2 convalescent plasma for Convalescent Plasma and 2 related conditions. Completed, enrolled 200 participants across 1 site.

Detailed Summary

Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConvalescent Plasma, COVID-19, SARS-CoV 2
CountriesNorth Macedonia
CollaboratorsUniversity Clinic for Infectious Diseases, North Macedonia

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMay 21, 2020
Enrollment StartApr 30, 2020
Primary CompletionMay 10, 2021
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 6.1 years ago

Interventions

anti-SARS-CoV-2 convalescent plasmabiological

Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection